TACSTD2 and ovarian carcinoma: Previously, it was reported that TROP2 is predominantly overexpressed in various tumor types, including UC, BC, cervical cancer, CRC, lung cancer, ovarian cancer, pancreatic cancer, thyroid cancer, endometrial cancer [12].